Investment Thesis
Gilead demonstrates exceptional financial health with industry-leading profitability metrics (28.9% net margin, 34.0% operating margin) and robust cash generation ($9.5B FCF). The company maintains a fortress balance sheet with strong liquidity (1.55x current ratio), excellent interest coverage (39.5x), and generates significant returns on equity (37.5%) despite moderate revenue growth of 2.4% YoY.
GILD Strengths
- Exceptional profitability with 28.9% net margin and 34.0% operating margin, demonstrating pricing power and operational efficiency
- Strong free cash flow generation of $9.5B (32.1% FCF margin) provides substantial capital for R&D, dividends, and strategic investments
- Fortress balance sheet with $7.6B cash, excellent interest coverage ratio of 39.5x, and manageable debt-to-equity ratio of 1.10x
- Superior returns on equity (37.5%) and return on assets (14.4%) indicate efficient capital deployment
- Solid liquidity position with 1.55x current ratio and 1.40x quick ratio provides financial flexibility
GILD Risks
- Revenue growth of only 2.4% YoY suggests maturation in core product portfolio and potential patent cliff exposure
- Significant long-term debt of $24.9B (1.10x equity) limits financial flexibility for major acquisitions or downturns, though well-managed by cash flows
- Pharmaceutical industry faces regulatory pressures, pricing scrutiny, and R&D pipeline risk that could impact future growth
- Extreme EPS growth of 1684.2% appears to reflect one-time items or restructuring rather than operational improvement, warranting investigation
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution to address modest 2.4% YoY growth
- Free cash flow sustainability and allocation strategy (R&D investment, M&A, shareholder returns)
- Gross margin trend and product mix evolution as legacy products face potential patent expirations
- Debt reduction progress relative to strong operating cash flow generation
GILD Financial Metrics
Revenue
$29.4B
Net Income
$8.5B
EPS (Diluted)
$6.78
Free Cash Flow
$9.5B
Total Assets
$59.0B
Cash Position
$7.6B
GILD Profitability Ratios
Gross Margin
20.1%
Operating Margin
34.0%
Net Margin
28.9%
ROE
37.5%
ROA
14.4%
FCF Margin
32.1%
GILD Balance Sheet & Liquidity
Current Ratio
1.55x
Quick Ratio
1.40x
Debt/Equity
1.10x
Debt/Assets
0.0%
Interest Coverage
39.46x
Long-term Debt
$24.9B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI